The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

INTRODUCTION: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Akazawa, Yuki, Igawa, Satoshi, Yamada, Kaori, Yamamoto, Hiroki, Yagami, Yuri, Kaizuka, Nobuki, Manaka, Hiroya, Kasajima, Masashi, Nakahara, Yoshiro, Sato, Takashi, Mitsufuji, Hisashi, Yokoba, Masanori, Kubota, Masaru, Sasaki, Jiichiro, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614514/
https://www.ncbi.nlm.nih.gov/pubmed/37166346
http://dx.doi.org/10.1159/000530809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614514/
https://www.ncbi.nlm.nih.gov/pubmed/37166346
http://dx.doi.org/10.1159/000530809

Ejemplares similares